AC Immune Stock Price, News & Analysis (NASDAQ:ACIU) $3.20 0.00 (0.00%) (As of 01:40 PM ET) Add Compare Share Share Today's Range$3.03▼$3.2150-Day Range$2.46▼$3.2452-Week Range$1.68▼$3.83Volume28,047 shsAverage Volume346,323 shsMarket Capitalization$267.58 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media AC Immune MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside400.0% Upside$16.00 Price TargetShort InterestBearish1.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.68) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 starsMedical Sector801st out of 949 stocksPharmaceutical Preparations Industry387th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingAC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, AC Immune has a forecasted upside of 400.0% from its current price of $3.20.Amount of Analyst CoverageAC Immune has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted1.36% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in AC Immune has recently increased by 5.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACIU. Previous Next 2.7 News and Social Media Coverage News SentimentAC Immune has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for AC Immune this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AC Immune to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of AC Immune is held by insiders.Percentage Held by InstitutionsOnly 19.17% of the stock of AC Immune is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.68) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AC Immune Stock (NASDAQ:ACIU)AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Read More ACIU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACIU Stock News HeadlinesNovember 20, 2023 | finance.yahoo.comFOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug successNovember 17, 2023 | morningstar.comAC Immune SA ACIUNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 9, 2023 | finance.yahoo.comAre Medical Stocks Lagging AC Immune (ACIU) This Year?November 7, 2023 | finance.yahoo.comAC Immune to Present at the Jefferies 2023 London Healthcare ConferenceNovember 3, 2023 | finance.yahoo.comAC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNovember 2, 2023 | finance.yahoo.comAC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023October 27, 2023 | finance.yahoo.comAC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease DiagnosticNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 24, 2023 | finance.yahoo.comIs AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?October 18, 2023 | finance.yahoo.comNeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock?October 17, 2023 | finance.yahoo.comAC Immune Announces Upcoming Presentations at the 16th CTAD ConferenceOctober 6, 2023 | finance.yahoo.comFurther weakness as AC Immune (NASDAQ:ACIU) drops 14% this week, taking five-year losses to 69%October 5, 2023 | finance.yahoo.comAC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023September 5, 2023 | finance.yahoo.comAre Options Traders Betting on a Big Move in AC Immune (ACIU) Stock?September 5, 2023 | finance.yahoo.comAC Immune (ACIU) Surges 43% in the Past 3 Months: Here's WhySeptember 5, 2023 | finance.yahoo.comAC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023August 7, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on AC Immune SA (ACIU)August 4, 2023 | finance.yahoo.comAC Immune (ACIU) Reports Q2 Loss, Misses Revenue EstimatesAugust 4, 2023 | finance.yahoo.comAC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateJuly 28, 2023 | finanznachrichten.deAC Immune SA: AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023July 28, 2023 | finance.yahoo.comAC Immune to Present at the BTIG Virtual Biotechnology Conference 2023July 26, 2023 | finance.yahoo.comAC Immune SA Appoints New Chief Medical OfficerJuly 3, 2023 | finance.yahoo.comAC Immune Showcasing Precision Medicine Programs at AAIC 2023July 2, 2023 | fool.comAc Immune (NASDAQ: ACIU)June 30, 2023 | finance.yahoo.comWhy Shares of AC Immune Jumped This WeekJune 28, 2023 | markets.businessinsider.comAC Immune SA (ACIU) Gets a Buy from H.C. WainwrightSee More Headlines Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACIU CUSIPN/A CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees126Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+401.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,140,000.00 Net MarginsN/A Pretax Margin-7,417,700.00% Return on Equity-46.44% Return on Assets-41.64% Debt Debt-to-Equity RatioN/A Current Ratio7.36 Quick Ratio7.36 Sales & Book Value Annual Sales$4.12 million Price / Sales64.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book1.88Miscellaneous Outstanding Shares83,620,000Free Float79,773,000Market Cap$266.75 million OptionableNot Optionable Beta0.72 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Andrea Pfeifer Ph.D. (Age 66)Co-Founder, CEO & Director Comp: $1.1MMr. Christopher Roberts (Age 34)Interim CFO & VP of Finance Mr. Piergiorgio Donati (Age 52)Chief Technical Operations Officer Dr. Marie Kosco-Vilbois (Age 65)Chief Scientific Officer Mr. Jean-Fabien Monin (Age 52)Chief Administrative Officer Mr. Howard Donovan (Age 48)Chief HR Officer Mr. Joshua Drumm Ph.D.Head of Investor RelationsMr. Alexandre Caratsch (Age 57)General Counsel Judith MooreGlobal Head of CommunicationsMr. Julian SnowVP of U.S. Finance & Corporate DevelopmentMore ExecutivesKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXProcaps GroupNASDAQ:PROCMineralys TherapeuticsNASDAQ:MLYSNuvation BioNYSE:NUVBPrecigenNASDAQ:PGENView All CompetitorsInstitutional OwnershipAvidity Partners Management LPBought 66,522 shares on 11/14/2023Ownership: 3.552%Tower Research Capital LLC TRC Bought 19,248 shares on 11/14/2023Ownership: 0.023%Group One Trading L.P.Sold 15,000 shares on 11/9/2023Ownership: 0.000%View All Institutional Transactions ACIU Stock Analysis - Frequently Asked Questions Should I buy or sell AC Immune stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACIU shares. View ACIU analyst ratings or view top-rated stocks. What is AC Immune's stock price target for 2024? 1 Wall Street analysts have issued 12-month price targets for AC Immune's shares. Their ACIU share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price. View analysts price targets for ACIU or view top-rated stocks among Wall Street analysts. How have ACIU shares performed in 2023? AC Immune's stock was trading at $2.04 at the beginning of 2023. Since then, ACIU stock has increased by 56.9% and is now trading at $3.20. View the best growth stocks for 2023 here. When is AC Immune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our ACIU earnings forecast. How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) posted its quarterly earnings data on Friday, November, 3rd. The company reported ($0.20) earnings per share for the quarter. What is Andrea Pfeifer's approval rating as AC Immune's CEO? 3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some companies that other AC Immune investors own include Sorrento Therapeutics (SRNE), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and AbbVie (ABBV). When did AC Immune IPO? (ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO. Who are AC Immune's major shareholders? AC Immune's stock is owned by a number of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (3.55%), Tower Research Capital LLC TRC (0.02%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ACIU) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.